![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RDX |
Gene summary for RDX |
![]() |
Gene information | Species | Human | Gene symbol | RDX | Gene ID | 5962 |
Gene name | radixin | |
Gene Alias | DFNB24 | |
Cytomap | 11q22.3 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | P35241 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5962 | RDX | LZE4T | Human | Esophagus | ESCC | 5.86e-15 | 4.55e-01 | 0.0811 |
5962 | RDX | LZE8T | Human | Esophagus | ESCC | 1.79e-07 | 1.06e-02 | 0.067 |
5962 | RDX | LZE20T | Human | Esophagus | ESCC | 1.81e-08 | 2.12e-01 | 0.0662 |
5962 | RDX | LZE24T | Human | Esophagus | ESCC | 8.62e-11 | 4.75e-01 | 0.0596 |
5962 | RDX | LZE6T | Human | Esophagus | ESCC | 4.29e-03 | -4.53e-02 | 0.0845 |
5962 | RDX | P1T-E | Human | Esophagus | ESCC | 1.88e-09 | 3.22e-01 | 0.0875 |
5962 | RDX | P2T-E | Human | Esophagus | ESCC | 1.70e-18 | 3.60e-01 | 0.1177 |
5962 | RDX | P4T-E | Human | Esophagus | ESCC | 1.40e-40 | 1.07e+00 | 0.1323 |
5962 | RDX | P5T-E | Human | Esophagus | ESCC | 9.33e-54 | 1.18e+00 | 0.1327 |
5962 | RDX | P8T-E | Human | Esophagus | ESCC | 1.00e-10 | 2.93e-01 | 0.0889 |
5962 | RDX | P9T-E | Human | Esophagus | ESCC | 6.81e-19 | 6.70e-01 | 0.1131 |
5962 | RDX | P10T-E | Human | Esophagus | ESCC | 1.38e-45 | 1.08e+00 | 0.116 |
5962 | RDX | P11T-E | Human | Esophagus | ESCC | 1.70e-27 | 1.43e+00 | 0.1426 |
5962 | RDX | P12T-E | Human | Esophagus | ESCC | 3.07e-38 | 9.01e-01 | 0.1122 |
5962 | RDX | P15T-E | Human | Esophagus | ESCC | 1.16e-15 | 4.37e-01 | 0.1149 |
5962 | RDX | P16T-E | Human | Esophagus | ESCC | 3.08e-22 | 4.33e-01 | 0.1153 |
5962 | RDX | P17T-E | Human | Esophagus | ESCC | 1.86e-05 | 6.31e-01 | 0.1278 |
5962 | RDX | P19T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.30e+00 | 0.1662 |
5962 | RDX | P20T-E | Human | Esophagus | ESCC | 1.17e-20 | 5.52e-01 | 0.1124 |
5962 | RDX | P21T-E | Human | Esophagus | ESCC | 1.49e-49 | 1.16e+00 | 0.1617 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:199074831 | Stomach | CAG | cellular detoxification | 16/552 | 116/18723 | 3.00e-07 | 2.39e-05 | 16 |
GO:000189431 | Stomach | CAG | tissue homeostasis | 25/552 | 268/18723 | 4.14e-07 | 3.13e-05 | 25 |
GO:006024931 | Stomach | CAG | anatomical structure homeostasis | 27/552 | 314/18723 | 7.25e-07 | 4.98e-05 | 27 |
GO:000697931 | Stomach | CAG | response to oxidative stress | 33/552 | 446/18723 | 1.33e-06 | 8.49e-05 | 33 |
GO:00988693 | Stomach | CAG | cellular oxidant detoxification | 14/552 | 101/18723 | 1.55e-06 | 9.34e-05 | 14 |
GO:200011631 | Stomach | CAG | regulation of cysteine-type endopeptidase activity | 22/552 | 235/18723 | 1.93e-06 | 1.11e-04 | 22 |
GO:00513463 | Stomach | CAG | negative regulation of hydrolase activity | 29/552 | 379/18723 | 3.03e-06 | 1.54e-04 | 29 |
GO:00019063 | Stomach | CAG | cell killing | 19/552 | 188/18723 | 3.13e-06 | 1.55e-04 | 19 |
GO:00104663 | Stomach | CAG | negative regulation of peptidase activity | 23/552 | 262/18723 | 3.39e-06 | 1.65e-04 | 23 |
GO:004586131 | Stomach | CAG | negative regulation of proteolysis | 27/552 | 351/18723 | 6.02e-06 | 2.75e-04 | 27 |
GO:00109513 | Stomach | CAG | negative regulation of endopeptidase activity | 22/552 | 252/18723 | 6.03e-06 | 2.75e-04 | 22 |
GO:006219731 | Stomach | CAG | cellular response to chemical stress | 26/552 | 337/18723 | 8.47e-06 | 3.67e-04 | 26 |
GO:000030231 | Stomach | CAG | response to reactive oxygen species | 20/552 | 222/18723 | 9.98e-06 | 4.15e-04 | 20 |
GO:004328131 | Stomach | CAG | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 19/552 | 209/18723 | 1.46e-05 | 5.69e-04 | 19 |
GO:007259331 | Stomach | CAG | reactive oxygen species metabolic process | 20/552 | 239/18723 | 2.93e-05 | 1.02e-03 | 20 |
GO:00427433 | Stomach | CAG | hydrogen peroxide metabolic process | 9/552 | 58/18723 | 4.63e-05 | 1.45e-03 | 9 |
GO:003459931 | Stomach | CAG | cellular response to oxidative stress | 22/552 | 288/18723 | 4.81e-05 | 1.49e-03 | 22 |
GO:000226231 | Stomach | CAG | myeloid cell homeostasis | 14/552 | 157/18723 | 2.34e-04 | 4.68e-03 | 14 |
GO:00454543 | Stomach | CAG | cell redox homeostasis | 6/552 | 35/18723 | 5.01e-04 | 8.50e-03 | 6 |
GO:003461431 | Stomach | CAG | cellular response to reactive oxygen species | 13/552 | 155/18723 | 6.94e-04 | 1.10e-02 | 13 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0453022 | Liver | Cirrhotic | Tight junction | 82/2530 | 169/8465 | 2.14e-07 | 2.85e-06 | 1.76e-06 | 82 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0520510 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
hsa0453032 | Liver | Cirrhotic | Tight junction | 82/2530 | 169/8465 | 2.14e-07 | 2.85e-06 | 1.76e-06 | 82 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0520511 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
hsa0453042 | Liver | HCC | Tight junction | 110/4020 | 169/8465 | 2.45e-06 | 2.28e-05 | 1.27e-05 | 110 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0520521 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
hsa0453052 | Liver | HCC | Tight junction | 110/4020 | 169/8465 | 2.45e-06 | 2.28e-05 | 1.27e-05 | 110 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0520531 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
hsa0520526 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0453030 | Oral cavity | OSCC | Tight junction | 102/3704 | 169/8465 | 8.68e-06 | 3.93e-05 | 2.00e-05 | 102 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RDX | SNV | Missense_Mutation | c.252C>G | p.Phe84Leu | p.F84L | P35241 | protein_coding | deleterious(0.01) | benign(0.224) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RDX | SNV | Missense_Mutation | c.1403N>T | p.Ser468Phe | p.S468F | P35241 | protein_coding | deleterious(0.03) | benign(0.409) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
RDX | SNV | Missense_Mutation | c.1495N>C | p.Glu499Gln | p.E499Q | P35241 | protein_coding | deleterious(0.02) | probably_damaging(0.932) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RDX | SNV | Missense_Mutation | c.344N>C | p.Ile115Thr | p.I115T | P35241 | protein_coding | deleterious(0) | possibly_damaging(0.693) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
RDX | SNV | Missense_Mutation | c.733A>T | p.Ile245Phe | p.I245F | P35241 | protein_coding | deleterious(0.02) | probably_damaging(0.936) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR | |
RDX | insertion | Frame_Shift_Ins | novel | c.639_640insTCTCATTTGATAAATAC | p.Thr214SerfsTer11 | p.T214Sfs*11 | P35241 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
RDX | insertion | Frame_Shift_Ins | novel | c.583_584insACATAACT | p.Ala195AspfsTer7 | p.A195Dfs*7 | P35241 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
RDX | insertion | In_Frame_Ins | novel | c.582_583insAAGTTACTA | p.Ile194_Ala195insLysLeuLeu | p.I194_A195insKLL | P35241 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
RDX | SNV | Missense_Mutation | rs780179741 | c.1706N>A | p.Arg569Gln | p.R569Q | P35241 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RDX | SNV | Missense_Mutation | novel | c.1369N>A | p.Glu457Lys | p.E457K | P35241 | protein_coding | tolerated(0.46) | possibly_damaging(0.832) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |